Report criticizes insulin giants for unequal access to medicines

The world’s poorest nations do not have access to insulin and manufacturers of the essential drug are not making new diabetes medicines available to them, says a report.

Photo: Novo Nordisk / PR/Henning Larsen Architects

The world’s biggest insulin makers, including Novo Nordisk, are too concerned with selling insulin to wealthy nations of Europe and the US, while people with diabetes in poorer countries don’t have access to the essential medicine, writes Finans citing a new report from the Access to Medicine Foundation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs